PLK4 Human shRNA Lentiviral Particle (Locus ID 10733)
SKU
TL320644V
PLK4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
$1,731.00
5 Weeks*
Specifications
| Product Data | |
| Locus ID | 10733 |
|---|---|
| Synonyms | MCCRP2; SAK; STK18 |
| Vector | pGFP-C-shLenti |
| E. coli Selection | Chloramphenicol (34 ug/ml) |
| Mammalian Cell Selection | Puromycin |
| Format | Lentiviral particles |
| Components | PLK4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
| RefSeq | NM_001190799, NM_001190801, NM_014264, NM_014264.1, NM_014264.2, NM_014264.3, NM_014264.4, NM_001190801.1, NM_001190799.1, BC036023, BC036023.1, NM_014264.5, NM_001190799.2 |
| UniProt ID | O00444 |
| Summary | This gene encodes a member of the polo family of serine/threonine protein kinases. The protein localizes to centrioles, complex microtubule-based structures found in centrosomes, and regulates centriole duplication during the cell cycle. Three alternatively spliced transcript variants that encode different protein isoforms have been found for this gene. provided by RefSeq, Jun 2010 |
| shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
| Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
| Storage | Store at -80°C |
| Shipping | Dry Ice |
Reviews
Documents
Resources
Citations
Polo‑like kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma
Wang, Zuo, Wang et al
Oncol. Rep. (2019)
Wang, Zuo, Wang et al
Oncol. Rep. (2019)
AI Summary: OriGene’s pGFP-shPLK4 lentivirus particles (cat. no. not specified) were used to knock down PLK4 expression in glioblastoma cells, enabling the study of PLK4’s role in tumor growth and radioresistance.
Snippet: After 24 h culture at 37˚C with 5% CO2, radiotherapy was performed in vitro using X‑RAD 320 from Precision X‑Ray at a dose of 12 Gy. Lentivirus transduction. pGFP‑shPLK4 lentivirus particles were purchased from OriGene Technologies, Inc. (cat. no
Showing 1-1 of 1 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
